Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Avalo Therapeutics (AVTX) Acquisitions (2017 - 2024)

Avalo Therapeutics filings provide 3 years of Acquisitions readings, the most recent being $356000.0 for Q1 2024.

On a quarterly basis, Acquisitions changed N/A to $356000.0 in Q1 2024 year-over-year; TTM through Dec 2024 was $356000.0, a N/A change, with the full-year FY2024 number at $356000.0, changed N/A from a year prior.
Acquisitions hit $356000.0 in Q1 2024 for Avalo Therapeutics, up from $1.0 in the prior quarter.
In the past five years, Acquisitions ranged from a high of $356000.0 in Q1 2024 to a low of $356000.0 in Q1 2024.